Zobrazeno 1 - 10
of 52
pro vyhledávání: ''
Autor:
Victoria C. Ziesenitz, Alexandre N. Datta, Tatjana Welzel, Peter Weber, Verena Gotta, Johannes N. van den Anker
Publikováno v:
British Journal of Clinical Pharmacology. 87:1568-1573
Sodium channel 2 subunit α (SCN2A) mutations cause difficult-to-treat early-onset epilepsy. Effective treatment includes high-dose phenytoin or carbamazepine ± ketogenic diet (KD). We describe an infant with early-onset SCN2A-epilepsy with subthera
Autor:
Heli Malm, Maarit K. Leinonen, Anna-Maria Lahesmaa-Korpinen, Aleksi Tornio, Mikko Niemi, Maria Ellfolk
Publikováno v:
British Journal of Clinical Pharmacology
Aims P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are efflux transporters expressed in the placenta, limiting their substrates from reaching the foetus. Our aim was to investigate if concomitant prenatal exposure to several subst
Autor:
Robbert J. van Alphen, Robert J. van Soest, Koen G A M Hussaarts, Esther Oomen-de Hoop, Paul Hamberg, Ron H.J. Mathijssen, Peter de Bruijn, Leonie J van Harten, Martijn P. Lolkema, Brigitte C M Haberkorn, Ronald de Wit, Bodine P.S. Belderbos
Publikováno v:
British Journal of Clinical Pharmacology, 85(5), 986-992. Wiley-Blackwell Publishing Ltd
Br J Clin Pharmacol
Br J Clin Pharmacol
Aims: Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso-enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the liv
Publikováno v:
Pastori, D, Mezzaroma, I, Pignatelli, P, Violi, F & Lip, G Y H 2019, ' Atrial fibrillation and Human Immunodeficiency Virus type-1 infection : a systematic review. Implications for anticoagulant and antiarrhythmic therapy ', British Journal of Clinical Pharmacology, vol. 85, no. 3, pp. 508–515 . https://doi.org/10.1111/bcp.13837
The prevalence and incidence of atrial fibrillation/flutter (AF/AFL) in patients with human immunodeficiency virus type-1 (HIV-1) infection have been poorly investigated. We performed a systematic review using PubMed and Cochrane Database of Systemat
Autor:
Kyriakos P. Papadopoulos, Zhengping Wang, R. Donald Harvey, Yang Xu, Alain C. Mita, Ying Ou, Dawn E. Pinchasik, Apostolia Maria Tsimberidou, Lia Gore, Richard E. Cutler
Publikováno v:
British Journal of Clinical Pharmacology. 85:530-539
Aims Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug t
Autor:
Martin Gutierrez, Alexey V. Danilov, Shekman Wong, Lionel D. Lewis, David Chien, Suresh Agarwal, Ahmed Salem, Soham D. Puvvada, Beibei Hu
Publikováno v:
British Journal of Clinical Pharmacology. 83:846-854
Aims To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. Methods Twelve patients with non-Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open-label
Autor:
Niels Hornstra, Anna Svedberg, Magnus Kentson, Anders Vikström, Henrik Gréen, Hirsh Koyi, Eva Brandén, Svante Vikingsson, Bengt Bergman
Publikováno v:
Br J Clin Pharmacol
Aims Erlotinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer highly metabolized by the cytochrome P450 (CYP) 3A. Hence, CYP3A4 activity might be a useful predictor of erlotinib pharmacokinetics in personalized med
Publikováno v:
British journal of clinical pharmacology. 85(1)
Aims To predict the optimal chemoprophylactic dose of mefloquine in infants of 5-10 kg using physiologically based pharmacokinetic (PBPK) and clinical effectiveness models. Methods The PBPK model was developed in Simcyp version 14.1 and verified agai
Publikováno v:
British Journal of Clinical Pharmacology
Aims The aim was to evaluate the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics (PK); the effect of dolutegravir on boceprevir and telaprevir PK was assessed through comparison with historical data for each hepatitis C virus (HC
Publikováno v:
British Journal of Clinical Pharmacology. 69:143-151
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • CP-690,550 is a novel JAK inhibitor in development as a therapy for rheumatoid arthritis. • Methotrexate is the cornerstone of combination treatment for rheumatoid arthritis. • The safety and tolerabil